The prevalence of peanut allergy (PA) in Africa is unknown but anecdotal reports suggest the prevalence to be lower than that experienced in developed countries, which report a prevalence of approximately 1.5%. Countries in Africa and Asia, as well as Israel, where the early consumption of high-dose peanut protein is routinely practised, have enjoyed a low prevalence of peanut allergy, e.g. 0.0...

BACKGROUND We previously reported the initial results of the first multicenter, randomized, double-blind, placebo-controlled clinical trial of peanut sublingual immunotherapy (SLIT), observing a favorable safety profile associated with modest clinical and immunologic effects in the first year. OBJECTIVE We sought to provide long-term (3-year) clinical and immunologic outcomes for our peanut S...

Background Peanut oral immunotherapy is both safe and effective in the treatment of children with peanut allergy but study protocols demand large resource commitment, limiting their adoption in routine clinical practice. We present 8 selected peanut allergic children who have achieved either full tolerance or an increased threshold to peanuts following a home based, low dose introduction of pea...

A mixed population of Meloidogyne arenaria race 1 and M. javanica race 3 is reported on peanut from a field in Levy County, Florida. Confirmation of M. javanica on peanut is based on esterase and malate dehydrogenase isozyme patterns resolved on polyacrylamide slab gels following electrophoresis, and perineal patterns. Up to 29% of 290 individual females collected from peanut roots in the field...

Methods In an open study design 460 children aged 5 to 30 months with AE and no detectable peanut-specific serum IgE will be divided into two groups. In Group A parents are advised to feed their children peanut at least three times a week, in Group B participating children strictly avoid peanut in their diet. Children are followed for one year. At the beginning and the end of the study standard...

Results 44 peanut allergic children (median age 5 years) reacted to peanut on DBPCPC with clinical symptoms than ranged from oral allergy syndrome to anaphylaxis. 61% of patients reacted to 0.1g of peanut protein. The mean %CD63+ basophil at 10 and 100 ng/ml of PE was independently associated with severity (p=0.012) whilst CD-sens (1/EC50x100) was independently associated with threshold (p=0.03...

Peanut (Arachis hypogaea) allergy is a major cause of food-induced anaphylaxis, with increasing prevalence worldwide. To date, there is no cure for peanut allergy, and, unlike many other food allergies, it usually persists through to adulthood. Prevention of exposure to peanuts is managed through strict avoidance, which can be compromised by the frequent use of peanuts and peanut products in fo...

Wild peanut species are useful genetic resources for improving the levels of disease/pest resistance and for enhancing the quality of seed composition by interspecific hybridization. The variation in oil content and fatty acid composition of wild peanut species in the United States Department of Agriculture germplasm collection is unknown. Seeds available from 39 wild species (plus a cultivated...

BACKGROUND Peanut allergenicity has been reported to be influenced by heat treatment, yet the commonly available extracts for skin prick testing (SPT) are derived from raw extracts. OBJECTIVE To assess the effect of heat treatment on the SPT reactivity and specific IgE binding to peanut. METHODS Three commercial extracts and 3 laboratory-prepared extracts, including raw, roasted, and boiled...

INTRODUCTION Peanut allergy is an increasingly serious disorder with a heterogeneous pattern of sensitization across different countries. In vitro diagnostic techniques may help in establishing these patterns. OBJECTIVES To analyze the usefulness of determining specific immunoglobulin E (sIgE) with the ImmunoCAP fluorescence enzyme immunoassay (FEIA), the ImmunoCAP ISAC CRD103 microarray (ISA...